^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    locnartecan (PEN-866)

    i
    Associations
    News

    Trials

    Company:
    Madrigal Pharma, National Cancer Institute - Bethesda, SciClone, Tarveda Therap
    Drug class:
    Topoisomerase I inhibitor, HSP90 inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors (NCT04890093)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    10/31/2024
    Primary completion :
    02/28/2026
    Completion :
    12/31/2026
    UGT1A1
    |
    UGT1A1*28 • UGT1A1*1*1
    |
    temozolomide • vincristine • locnartecan (PEN-866)
    PEN-866 in Patients With Advanced Solid Malignancies (NCT03221400)
    Phase 1/2
    Tarveda Therapeutics
    Recruiting
    Last update posted :
    02/17/2022
    Initiation :
    08/29/2017
    Primary completion :
    01/01/2023
    Completion :
    06/01/2023
    HSP90AA1
    |
    5-fluorouracil • Zejula (niraparib) • irinotecan • leucovorin calcium • locnartecan (PEN-866)